Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
Background Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients with non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death-ligand 1 (PD-L1). However, appropriate treatment for patients showing high PD-L1 expression and poor performance status (PS) is not well defined. Objective The aim of this study was to identify a treatment option that is better for these patients in a real-world setting. Patients and Methods A total of 425 patients with NSCLC and high PD-L1 expression were included retrospectively. All patients received either pembrolizumab monotherapy or ICI plus chemotherapy as the first-line treatment. Patients were subdivided into good (PS score 0 or 1; n = 354) and poor PS groups (PS score 2 or 3; n = 71). Early progressive disease (PD) was defined as PD within 3 months of ICI-based therapy initiation. Results The good PS group had significantly longer progression-free survival (PFS) and overall survival (OS) than the poor PS group upon ICI-based therapy administration. In the poor PS group, no significant difference was observed in PFS and OS between pembrolizumab monotherapy and ICI plus chemotherapy. In the good PS group, pembrolizumab monotherapy, PD-L1 50–89%, and liver metastasis were associated with early PD, as determined using multivariate logistic regression analyses. However, in the poor PS group, the multivariate logistic regression analyses did not show an association between pembrolizumab monotherapy and early PD. Conclusions In patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Targeted oncology - 18(2023), 6 vom: 30. Okt., Seite 915-925 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morimoto, Kenji [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11523-023-01012-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053815491 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053815491 | ||
| 003 | DE-627 | ||
| 005 | 20231122064741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231122s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-023-01012-1 |2 doi | |
| 035 | |a (DE-627)SPR053815491 | ||
| 035 | |a (SPR)s11523-023-01012-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morimoto, Kenji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients with non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death-ligand 1 (PD-L1). However, appropriate treatment for patients showing high PD-L1 expression and poor performance status (PS) is not well defined. Objective The aim of this study was to identify a treatment option that is better for these patients in a real-world setting. Patients and Methods A total of 425 patients with NSCLC and high PD-L1 expression were included retrospectively. All patients received either pembrolizumab monotherapy or ICI plus chemotherapy as the first-line treatment. Patients were subdivided into good (PS score 0 or 1; n = 354) and poor PS groups (PS score 2 or 3; n = 71). Early progressive disease (PD) was defined as PD within 3 months of ICI-based therapy initiation. Results The good PS group had significantly longer progression-free survival (PFS) and overall survival (OS) than the poor PS group upon ICI-based therapy administration. In the poor PS group, no significant difference was observed in PFS and OS between pembrolizumab monotherapy and ICI plus chemotherapy. In the good PS group, pembrolizumab monotherapy, PD-L1 50–89%, and liver metastasis were associated with early PD, as determined using multivariate logistic regression analyses. However, in the poor PS group, the multivariate logistic regression analyses did not show an association between pembrolizumab monotherapy and early PD. Conclusions In patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy. | ||
| 700 | 1 | |a Yamada, Tadaaki |0 (orcid)0000-0002-6945-281X |4 aut | |
| 700 | 1 | |a Kawachi, Hayato |4 aut | |
| 700 | 1 | |a Tamiya, Motohiro |4 aut | |
| 700 | 1 | |a Negi, Yoshiki |4 aut | |
| 700 | 1 | |a Goto, Yasuhiro |4 aut | |
| 700 | 1 | |a Nakao, Akira |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |4 aut | |
| 700 | 1 | |a Tanimura, Keiko |4 aut | |
| 700 | 1 | |a Takeda, Takayuki |4 aut | |
| 700 | 1 | |a Okada, Asuka |4 aut | |
| 700 | 1 | |a Harada, Taishi |4 aut | |
| 700 | 1 | |a Date, Koji |4 aut | |
| 700 | 1 | |a Chihara, Yusuke |4 aut | |
| 700 | 1 | |a Hasegawa, Isao |4 aut | |
| 700 | 1 | |a Tamiya, Nobuyo |4 aut | |
| 700 | 1 | |a Nishioka, Naoya |4 aut | |
| 700 | 1 | |a Katayama, Yuki |4 aut | |
| 700 | 1 | |a Iwasaku, Masahiro |4 aut | |
| 700 | 1 | |a Tokuda, Shinsaku |4 aut | |
| 700 | 1 | |a Kijima, Takashi |4 aut | |
| 700 | 1 | |a Takayama, Koichi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d Paris : Springer Verlag France S.A.R.L., 2006 |g 18(2023), 6 vom: 30. Okt., Seite 915-925 |w (DE-627)SPR020528167 |w (DE-600)2222136-0 |x 1776-260X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:6 |g day:30 |g month:10 |g pages:915-925 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11523-023-01012-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 6 |b 30 |c 10 |h 915-925 | ||